News & Updates

Show Multimedia Only
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer

CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer

08 Mar 2023
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

08 Mar 2023 byJairia Dela Cruz

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

08 Mar 2023
Longer time in BP target protects against adverse cardiovascular events in diabetes

Longer time in BP target protects against adverse cardiovascular events in diabetes

08 Mar 2023

For patients with hypertension and diabetes, longer time spent in blood pressure (BP) target range helps lower the risk of cardiovascular disease, according to a study.

Longer time in BP target protects against adverse cardiovascular events in diabetes

08 Mar 2023
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?

08 Mar 2023 byNatalia Reoutova

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?

08 Mar 2023
Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

07 Mar 2023

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

07 Mar 2023
Nitrogen dioxide exposure ups risk of IPF progression

Nitrogen dioxide exposure ups risk of IPF progression

07 Mar 2023

Patients with idiopathic pulmonary fibrosis (IPF) who have high exposure to nitrogen dioxide (NO2) are at greater risk of disease progression, suggests a recent study.

Nitrogen dioxide exposure ups risk of IPF progression

07 Mar 2023
Local plus systemic therapies improve survival in HCC

Local plus systemic therapies improve survival in HCC

07 Mar 2023 byStephen Padilla

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

Local plus systemic therapies improve survival in HCC

07 Mar 2023